Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics 2020 Revenues Spike on Coronavirus Testing

NEW YORK — Co-Diagnostics on Thursday posted revenues of $74.6 million for 2020, a sharp increase over the $214,974 in revenues the firm reported the year before, primarily due to sales of its Logix Smart COVID-19 test for SARS-CoV-2.

The PCR-based test received the CE-IVD mark in February 2020 and Emergency Use Authorization from the US Food and Drug Administration a couple of months later. Sales of Logix Smart COVID-19 accounted for the lion's share of Co-Diagnostics' revenues for 2020.

"Demand for our Logix Smart COVID-19 test drove record sales this year and, although COVID-19 test sales may not be as robust as in 2020, we anticipate demand for our portfolio of products to continue in 2021," Co-Diagnostics CEO Dwight Egan said in a statement. "As the world seeks normalization, we anticipate continued demand for our COVID-19 tests and other diagnostic products as testing becomes a part of the long-term protocol for many organizations."

In 2019, the majority of Co-Diagnostics' revenues came from sales of equipment and tests for the detection of mosquito-borne viruses in abatement districts.

For the 12-month period ended Dec. 31, Co-Diagnostics reported a net profit of $42.5 million, or $1.52 per share, versus a year-ago loss of $6.2 million, or $.37 per share.

Its R&D spending in 2020 jumped 129 percent to $3.2 million from $1.4 million, primarily due to an increase in salaries and related benefits as Co-Diagnostics added additional employees to support growing product development efforts. Its SG&A costs, meantime, climbed 182 percent to $13.0 million from $4.6 million on higher employee-related expenses.

At the end of 2020, Salt Lake City-based Co-Diagnostics had cash and cash equivalents totaling $43.0 million and marketable investment securities of $4.3 million.

For the fourth quarter of 2020, Co-Diagnostics posted revenues of $27.1 million and a net profit of $12.8 million, or $.43 per share.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.